Jane Stocks1, Karteek Popuri2, Ashley Heywood1, Duygu Tosun3, Kate Alpert1, Mirza Faisal Beg2, Howard Rosen3, Lei Wang1,4. 1. Department of Psychiatry and Behavioral Sciences Feinberg School of Medicine Northwestern University Chicago Illinois USA. 2. School of Engineering Science Simon Fraser University Burnaby British Columbia Canada. 3. School of Medicine University of California San Francisco, California USA. 4. Department of Psychiatry and Behavioral Health Ohio State University Wexner Medical Center Columbus Ohio USA.
Abstract
Background: Concordance between cortical atrophy and cortical glucose hypometabolism within distributed brain networks was evaluated among cerebrospinal fluid (CSF) biomarker-defined amyloid/tau/neurodegeneration (A/T/N) groups. Method: We computed correlations between cortical thickness and fluorodeoxyglucose metabolism within 12 functional brain networks. Differences among A/T/N groups (biomarker normal [BN], Alzheimer's disease [AD] continuum, suspected non-AD pathologic change [SNAP]) in network concordance and relationships to longitudinal change in cognition were assessed. Results: Network-wise markers of concordance distinguish SNAP subjects from BN subjects within the posterior multimodal and language networks. AD-continuum subjects showed increased concordance in 9/12 networks assessed compared to BN subjects, as well as widespread atrophy and hypometabolism. Baseline network concordance was associated with longitudinal change in a composite memory variable in both SNAP and AD-continuum subjects. Conclusions: Our novel study investigates the interrelationships between atrophy and hypometabolism across brain networks in A/T/N groups, helping disentangle the structure-function relationships that contribute to both clinical outcomes and diagnostic uncertainty in AD.
Background: Concordance between cortical atrophy and cortical glucose hypometabolism within distributed brain networks was evaluated among cerebrospinal fluid (CSF) biomarker-defined amyloid/tau/neurodegeneration (A/T/N) groups. Method: We computed correlations between cortical thickness and fluorodeoxyglucose metabolism within 12 functional brain networks. Differences among A/T/N groups (biomarker normal [BN], Alzheimer's disease [AD] continuum, suspected non-AD pathologic change [SNAP]) in network concordance and relationships to longitudinal change in cognition were assessed. Results: Network-wise markers of concordance distinguish SNAP subjects from BN subjects within the posterior multimodal and language networks. AD-continuum subjects showed increased concordance in 9/12 networks assessed compared to BN subjects, as well as widespread atrophy and hypometabolism. Baseline network concordance was associated with longitudinal change in a composite memory variable in both SNAP and AD-continuum subjects. Conclusions: Our novel study investigates the interrelationships between atrophy and hypometabolism across brain networks in A/T/N groups, helping disentangle the structure-function relationships that contribute to both clinical outcomes and diagnostic uncertainty in AD.
In sporadic Alzheimer's disease (AD), beginning years before clinical symptom onset, a cascade of pathophysiological changes occur involving the aggregation of amyloid beta (Aβ) and tau proteins leading to neurodegeneration.
An ongoing challenge in the study of AD is that of clinic‐anatomical convergence, indicating the same clinical syndrome can be caused by different underlying pathological entities.
To this end, the “A/T/N” framework
has emphasized biomarkers as ante mortem predictors of AD pathology. Based on the presence/absence of markers of Aβ (A), phosphorylated tau (T), and neurodegeneration (N) in either the cerebrospinal fluid (CSF) or neuroimaging, the A/T/N classification schema results in three categories of biomarker abnormality: biomarker “normal” (BN; A–T–N–), “AD continuum” (any A+ category), and suspected “non‐AD pathologic change” (i.e., SNAP, A– with either T+ or N+). Among these categories, SNAP has been proposed to represent a distinct pathological, clinical, and cognitive disease process from AD.
,
However, its cognitive profile, longitudinal trajectory, and post mortem pathology remain less well understood.Structural magnetic resonance imaging (MRI) and positron emission tomography with 18F‐fluorodeoxyglucose (18FDG‐PET) have been used to measure brain atrophy and glucose hypometabolism, respectively. Multimodal analysis of anatomical and physiological change allows for the development of dynamic models of pathophysiological processes and can increase the power to characterize heterogeneity in clinical presentations of neurodegenerative disease processes.
Multimodal neuroimaging can measure the degree to which signals generated by each modality mirror the other in their strength, spatial distribution, or temporal ordering.
Termed “concordance,” these markers have been used to directly compare patterns of brain atrophy and hypometabolism across different dementias.
,
Bejanin et al.
suggested that neurodegenerative disorders with a more unitary underlying pathophysiological disease process (i.e., semantic dementia due to TDP‐43 Type C) may show higher concordance between hypometabolism and atrophy compared to a more multidetermined disease process (i.e., Aβ, tau in AD). However, prior studies measured concordance at the whole‐brain or whole‐lobe level, providing only a limited description of the link between structure and function in the brain. Given neurodegenerative diseases are hypothesized to spread along, and reflect damage to, large‐scale brain networks spanning multiple regions,
,
network‐based characterization of multimodal neuroimaging features can improve our understanding of the disease processes.Studies have indicated that the neuroimaging patterns of cortical atrophy and glucose hypometabolism observed in AD continuum more closely resemble in vivo PET markers of tau than amyloid.
While SNAP individuals have positive markers of tau pathology on CSF, reported relationships between CSF phosphorylated tau (p‐tau) and tau‐PET has ranged from mild to strong and may vary by disease stage and the presence of amyloid.
Therefore, it is unclear whether structure–function concordance will occur in SNAP subjects, despite the observed relationship between tau and markers of neurodegeneration in AD.
This knowledge could aid in understanding the causes of neurodegeneration among this understudied group and provide information to allow treatment development that is tailored to the pathophysiology of the disease. Here, we computed maps of concordance between cortical atrophy and hypometabolism across the brain's functional networks for each individual, compared across A/T/N groups, and related them to longitudinal cognitive changes. We hypothesized that concordance would uniquely discriminate the A/T/N groups and be more sensitive than unimodal measures to future cognitive decline.
RESEARCH IN CONTEXT
Systematic Review: Concordance of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging differentiate Alzheimer's disease (AD) from frontotemporal lobar dementia (FTLD), but prior work focused on whole‐brain analyses, despite evidence that neurodegenerative disorders spread within circumscribed, selectively vulnerable brain networks. It remains unclear whether network‐wise multimodal concordance can differentiate biomarker‐normal individuals from AD continuum and suspected non‐AD pathologic change (SNAP).Interpretation: Findings support evidence that SNAP is a heterogeneous group regarding etiology; however, network‐wise multimodal indicators of neurodegeneration are superior for distinguishing SNAP from biomarker normal subjects and for association with longitudinal change in memory.Future Directions: Future research should examine whether increased concordance within the select networks represents a potential biomarker of neuropathologic change among SNAP individuals who progress to an FTLD syndrome. Further, future work could also examine those who are only amyloid positive (e.g., A+T–N–) as a distinct group or use data‐driven measures of concordance (e.g., canonical correlation) for additional computational power.
MATERIAL AND METHODS
Participants
Data were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. ADNI was launched in 2003 as a public–private partnership, led by principal investigator Michael W. Weiner, MD. The primary goal of ADNI is to test whether serial MRI, PET, other biological markers, and clinical and neuropsychological assessment can be used to understand disease progression in mild cognitive impairment (MCI) and AD. Full details of participant recruitment, scanning protocols, diagnostic criteria, as well as imaging and CSF data processing are available at www.adni‐info.org. ADNI protocols can be found in Jack et al.
and Mueller et al.
For this study, we included participants who had baseline CSF, structural MRI and 18FDG‐PET data, and neuropsychological testing data at both baseline and 12‐month follow‐up visits, to measure cognitive change. Twelve months was selected as a follow‐up interval to retain the maximum number of participants and to allow sufficient time for cognitive change.CSF samples were analyzed at the University of Pennsylvania, according to procedures and recommendations in the ADNI procedures manual, using Elecsys CSF immunoassays. Elecsys assays are fully automated, run on the Cobas e 601 analyzer (Roche Diagnostics GmbH) and have been reported to avoid the observed interlaboratory variation and upward drift of Aβ42 values seen in enzyme‐linked immunosorbent assays.
Based on CSF measures of Aβ1‐42, phosphorylated tau 181 (p‐tau), and total tau (t‐tau), we first designated A/T/N positivity using published cut‐off points:
Aβ1‐42 < 977 pg/mL for A+/A–, p‐tau > 23 pg/ml for T+/T–, and t‐tau > 213 pg/ml for N+/N–. We then designated the participants into the following A/T/N groups: BN (participants who were A–T–N–), AD continuum (amyloid‐positive, i.e., A+T–N–, A+T–N+, A+T+N–, A+T+N+), or SNAP (the remaining amyloid‐negative, i.e., A–T–N+, A–T+N–, A–T+N+).
Image processing
Structural MRI
ADNI MRI preprocessing included correction of geometric distortion, non‐uniformity normalization, and histogram‐peak sharpening. We processed all preprocessed MRI data with FreeSurfer v5.3
to generate cortical thickness measures with quality control by visual inspection. Erroneous segmentations were corrected according to FreeSurfer protocol. Sixteen scans were removed from further analysis due to large or immutable errors (Figure S1 in supporting information). Fourteen mm full width half maximum (FWHM) kernel was applied to the cortical thickness data along the cortical surface.
The cortical thickness data were then mapped onto the fsaverage template surface.
18FDG‐PET
Detailed ADNI preprocessing for 18FDG‐PET included co‐registration, averaging, standardizing spatial resolution, orientation and normalization, and scanner‐specific smoothing to achieve a uniform smoothing level of isotropic 8 mm FWHM. We co‐registered all preprocessed 18FDG‐PET data with their respective MRI images using FSL‐FLIRT,
using nine degrees of freedom and normalized correlation as the cost function. Cortical 18FDG‐PET uptake values were then re‐indexed to the fsaverage template white surface and smoothed with a Gaussian smoothing kernel of 14 mm FWHM to achieve the same effective smoothness as the cortical thickness data.
W‐score maps
The above MRI and 18FDG‐PET processing resulted in multimodal vectors of cortical thickness and 18FDG‐PET uptake, correspondingly indexed over the fsaverage template surface and smoothed to the same degree across all participants. Next, we computed vertex‐wise W‐scores
for cortical thickness and 18FDG‐PET uptake to adjust for the effects of normal aging (Figure 1A). W‐scores were calculated by fitting a general linear model (GLM) against age in a set of reference participants, and taking the standardized residuals generated from this model for all participants:
W = ([raw value] – [expected value])/(standard deviation of the residuals of reference). For the reference set, we used cognitively normal individuals without a clinical diagnosis who do not progress to MCI or AD throughout the ADNI period (see Popuri et al.
). In our sample, the reference set comprised 423 subjects, 53% female, with a mean age of 74.4 (5.95).
FIGURE 1
Sample participant to demonstrate methods used for the network concordance analyses. A, Within each individual, vertex‐wise magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG‐PET) W‐Scores were parcellated into 360 cortical patches, and in (B) Pearson correlations between FDG‐PET hypometabolism were computed per participant across the patches in each of 12 functional networks defined by Ji et al.
Sample participant to demonstrate methods used for the network concordance analyses. A, Within each individual, vertex‐wise magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG‐PET) W‐Scores were parcellated into 360 cortical patches, and in (B) Pearson correlations between FDG‐PET hypometabolism were computed per participant across the patches in each of 12 functional networks defined by Ji et al.
Analyses
Participants
Differences in demographic and clinical variables across the A/T/N groups were assessed with two‐way analysis of variance (ANOVA) for continuous data and Chi‐square testing for categorical data, with post hoc comparisons wherever relevant. See Table 1.
TABLE 1
Table showing summary of demographic variables
BN
SNAP
AD continuum
Post hoc test (P)
n: 179
n: 149
n: 559
P
AD‐C vs. BN
SNAP vs. BN
AD‐C vs. SNAP
Age
71.22 (7.5)
73.51 (6.8)
73.61 (6.8)
< .001
< .001
0.005
–
Male: Female
88:91
70:79
239:320
–
–
–
–
Education
16.3 (2.6)
16.2 (2.6)
16.0 (3.1)
–
–
–
–
CDR‐SB
0.63 (0.8)
0.94 (1.3)
2.0 (1.9)
< .001
< .001
< .001
APOE ε4 Y: N
31:148
38:111
346:213
< .001
< .001
–
–
MMSE
24–30 (1.4)
21–30 (1.9)
19–30 (2.8)
< .001
< .001
–
< .001
ADNI‐Mem
0.92 (0.7)
0.65 (0.7)
–0.058 (0.9)
< .001
< .001
0.003
< .001
ADNI‐EF
0.82 (0.8)
0.67 (1.0)
–0.14 (1.3)
< .001
< .001
–
< .001
ATN subgroups
179 A–T–N–
102 A–T+N+
355 A+T+N+
47 A–T–N+
179 A+T–N–
25 A+T–N+
3 A+T+N–
Clinical diagnosis (CN/MCI/dementia)
96/79/4
67/71/11
95/303/161
< .001
Aβ pg/ml
1551 (316)
1943 (575)
675 (201)
< .001
< .001
< .001
< .001
P‐tau pg/ml
15.9 (2.8)
28.9 (10.1)
31.5 (15.9)
< .001
< .001
< .001
–
T‐tau pg/ml
183 (30.1)
322 (97.6)
315 (144)
< .001
< .001
< .001
–
Notes: Results are reported as mean (std) for continuous variables or counts for discrete variables, and t‐statistic and P‐value for post hoc pairwise analyses compared to BN subjects where ANOVA was significant. Age and education are reported in years. N's for ADNI‐Mem and ADNI‐EF annual rate of change reflect subjects with data for both baseline and 1‐year assessments of neuropsychological function.
a For ADNI‐Mem and ADNI‐EF annual rate of change reflect significance in the direction change.
Table showing summary of demographic variablesNotes: Results are reported as mean (std) for continuous variables or counts for discrete variables, and t‐statistic and P‐value for post hoc pairwise analyses compared to BN subjects where ANOVA was significant. Age and education are reported in years. N's for ADNI‐Mem and ADNI‐EF annual rate of change reflect subjects with data for both baseline and 1‐year assessments of neuropsychological function.a For ADNI‐Mem and ADNI‐EF annual rate of change reflect significance in the direction change.Abbreviations: Aβ, amyloid beta; AD, Alzheimer's disease; AD‐C, Alzheimer's disease continuum; ADNI‐EF, Alzheimer's Disease Neuroimaging Initiative Executive Functioning Composite; ADNI‐Mem, Alzheimer's Disease Neuroimaging Initiative Memory Composite; ANOVA, analysis of variance; APOE, apolipoprotein E; BN, biomarker normal; CDR‐SB, Clinical Dementia Rating–Sum of Boxes; CN, cognitively normal ; MCI, mild cognitive impairment; MMSE, Mini Mental State Examination; p‐tau, phosphorylated tau; SNAP, suspected non‐Alzheimer's disease pathologic change; t‐tau, total tau.
Network‐wise unimodal atrophy, hypometabolism, and multimodal concordance
Using the Human Connectome Project‐MMP1 atlas
that is based on multimodal features including cytoarchitecture and functional connectivity, the fsaverage template surface was parcellated into 360 patches corresponding to select cortical vertices (Figure 1A). These patches have been grouped into 12 functional networks by Ji et al.
via a community detection algorithm using resting‐state data from healthy adults.For unimodal analysis, the mean W‐scores of cortical thickness and 18FDG‐PET uptake within each network were calculated. Each network‐wise unimodal measure of cortical thickness and 18FDG‐PET uptake was entered into a separate GLM with A/T/N group as the main effect and sex, apolipoprotein E (APOE) ε4 status, Clinical Dementia Rating scale Sum of Boxes (CDR‐SB),
and education as covariates. Post hoc tests contrasted AD continuum and SNAP groups with BN. For each group pair, this produced a coefficient estimate and pooled standard error for group, from which a t‐statistic was calculated and visualized as a color map on the overall average surface. In these and all subsequent analyses described below, significance levels were corrected for multiple comparisons by applying a false discovery rate (FDR) of 0.05.For multimodal analysis, a concordance measure was calculated for each individual as the Pearson correlation coefficient between patch‐wise W‐scores of cortical thickness and 18FDG‐PET uptake for each network (Figure 1B). The main effect of A/T/N group and contrasts between AD continuum, SNAP, and BN groups on multimodal network concordance were examined across all networks in the same manner as for the unimodal measures described above. Analyses were performed using the MATLAB 2018b
package SurfStat (http://www.math.mcgill.ca/keith/surfstat).
Network concordance by cognitive screening measure
Clinical heterogeneity exists within the A/T/N groups. Some individuals in AD continuum and SNAP may carry amyloid and tau pathologies but exhibit normal levels of cognition (see Table 1 Mini Mental State Examination [MMSE] range). The MMSE score of 26 has been shown to be an optimal threshold for dementia screening with 72% sensitivity and 94% specificity.
We therefore used this threshold to examine network concordance in cognitively impaired (CI) and cognitively unimpaired (CU) AD continuum and SNAP groups compared to unimpaired BN individuals using a GLM with age, sex, APOE ε4 status, CDR‐SB, and education as covariates.
Relationship to cognitive change
Cognition was assessed for each individual using composite scales for memory and executive function (i.e., ADNI‐Mem
and ADNI‐EF,
respectively), calculated based on the ADNI neuropsychological battery. We calculated an annual rate of change for ADNI‐Mem and ADNI‐EF using linear mixed effects models. Age, sex, education, CDR‐SB, and APOE ε4 status were used as fixed effects, and random slope and intercept were used for time. Differences in annual rates of change in ADNI‐Mem and ADNI‐EF between groups were evaluated using two‐sample t‐tests. Rates of change were then regressed against network concordance across all networks with age, sex, education, APOE ε4 status, and CDR‐SB as covariates. To assess the contribution of concordance beyond unimodal atrophy and hypometabolism alone, the mean W‐score of atrophy and hypometabolism were included as covariates. Analyses were performed using R
with the nlme package.
RESULTS
At baseline, AD continuum (N = 559) and SNAP (N = 149) were older than BN (N = 179) (P<.05). AD continuum showed the greatest frequency of APOE ε4 carriers (P<.001). MMSE, ADNI‐Mem, ADNI‐EF, and 1‐year rate of change of ADNI‐Mem were lower in AD continuum compared to BN (all P<.001). Baseline ADNI‐Mem was lower in SNAP compared to BN (P<.01). No significant differences were detected between SNAP and BN on baseline ADNI‐EF, ADNI‐Mem rate of change, or ADNI‐EF rate of change. As expected, CSF measures of Aβ were lower while p‐tau and t‐tau values were greater in AD continuum than in BN (all P<.001). P‐tau and t‐tau values were greater, as expected, in SNAP than in BN (all P<.001); however, CSF Aβ values were greater in SNAP than BN (P<.001). See Table 1.
Network‐wise patterns of cortical atrophy, hypometabolism, and concordance among A/T/N groups
Figure 2 displays the W‐score maps of cortical atrophy, hypometabolism, and concordance in each A/T/N group. Figure 3 displays comparisons of hypometabolism, atrophy, and concordance in AD continuum and SNAP versus BN. While SNAP showed no network‐wise differences from BN in atrophy or hypometabolism, they showed greater atrophy–hypometabolism concordance in the language and posterior multimodal networks. AD continuum showed widespread hypometabolism affecting all networks except the somatomotor, primary and secondary visual networks, and cortical atrophy in all but the somatomotor and primary visual networks. AD continuum also showed increased concordance among secondary visual, somatomotor, cingulo‐opercular, dorsal attention, language, auditory, frontoparietal, default mode, posterior and ventral multimodal networks. Regarding effects of covariates, APOE ε4 positivity resulted in increased FDG‐PET hypometabolism in all three groups among the secondary visual, dorsal attention, and ventral multimodal networks. No other significant effects of included covariates were noted.
FIGURE 2
Within‐group means of network‐wise fluorodeoxyglucose positron emission tomography (FDG‐PET) hypometabolism (A), cortical atrophy (B), and concordance (C) among ATN subgroups, displayed on the brain (left images) and in graphical format (right). Alterations within biomarker normal (BN; N = 179), suspected non‐Alzheimer's disease pathologic change (SNAP; N = 149), and Alzheimer's disease continuum (N = 559) are expressed as mean W‐score within each network for FDG‐PET and atrophy, and mean Pearson correlation for concordance
FIGURE 3
T‐scores of false discovery rate–corrected significant networks in suspected non‐Alzheimer's disease pathologic change (SNAP; N = 149) and Alzheimer's disease (AD) continuum (N = 559) groups compared to biomarker normal (BN; N = 179) participants in W‐score transformed cortical thickness (top panel), W‐score transformed fluorodeoxyglucose positron emission tomography (FDG‐PET) hypometabolism (middle panel), and network concordance (bottom panel) after controlling for sex, education, apolipoprotein E ε4. SNAP showed no significant differences from BN in atrophy or hypometabolism after multiple comparisons correction. SNAP showed increased network concordance compared to BN in the language and posterior multimodal networks. AD continuum showed widespread hypometabolism in all but somatomotor, primary and secondary visual networks and significantly increased atrophy in all but somatomotor and primary visual networks. AD continuum showed increased concordance among secondary visual, somatomotor, cingulo‐opercular, dorsal attention, language, auditory, frontoparietal, default mode, posterior, and ventral multimodal networks
Within‐group means of network‐wise fluorodeoxyglucose positron emission tomography (FDG‐PET) hypometabolism (A), cortical atrophy (B), and concordance (C) among ATN subgroups, displayed on the brain (left images) and in graphical format (right). Alterations within biomarker normal (BN; N = 179), suspected non‐Alzheimer's disease pathologic change (SNAP; N = 149), and Alzheimer's disease continuum (N = 559) are expressed as mean W‐score within each network for FDG‐PET and atrophy, and mean Pearson correlation for concordanceT‐scores of false discovery rate–corrected significant networks in suspected non‐Alzheimer's disease pathologic change (SNAP; N = 149) and Alzheimer's disease (AD) continuum (N = 559) groups compared to biomarker normal (BN; N = 179) participants in W‐score transformed cortical thickness (top panel), W‐score transformed fluorodeoxyglucose positron emission tomography (FDG‐PET) hypometabolism (middle panel), and network concordance (bottom panel) after controlling for sex, education, apolipoprotein E ε4. SNAP showed no significant differences from BN in atrophy or hypometabolism after multiple comparisons correction. SNAP showed increased network concordance compared to BN in the language and posterior multimodal networks. AD continuum showed widespread hypometabolism in all but somatomotor, primary and secondary visual networks and significantly increased atrophy in all but somatomotor and primary visual networks. AD continuum showed increased concordance among secondary visual, somatomotor, cingulo‐opercular, dorsal attention, language, auditory, frontoparietal, default mode, posterior, and ventral multimodal networksFigure 4 shows comparisons of hypometabolism, atrophy, and concordance in AD continuum and SNAP versus BN after additionally controlling for clinical severity as measured by CDR‐SB. Significant effects of CDR‐SB were seen across all modalities, groups, and networks. In this model, SNAP showed no significant differences from BN in atrophy or hypometabolism but showed greater network concordance in the language and posterior multimodal networks. AD continuum showed greater hypometabolism in the frontoparietal, default mode, and posterior multimodal networks, and greater cortical atrophy in the ventral multimodal network only. AD continuum showed increased concordance among all except the primary visual and orbito‐affective networks. Previously noted observed effects of APOE ε4 positivity remained significant in the analyses controlling for CDR‐SB. Significant differences between AD continuum and SNAP groups in unimodal and concordance measures, with and without CDR‐SB included as a covariate, can be found in Figure S2 in supporting information.
FIGURE 4
T‐scores of false discovery rate–corrected significant networks in suspected non‐Alzheimer's disease pathologic change (SNAP; N = 149) and Alzheimer's disease (AD) continuum (N = 559) groups compared to biomarker normal (BN; N = 179) in W‐score transformed cortical thickness (top panel), fluorodeoxyglucose positron emission tomography (FDG‐PET) hypometabolism (middle panel), and network concordance (bottom panel) after controlling for sex, education, apolipoprotein E ε4, and Clinical Dementia Rating‐Sum of Boxes. SNAP showed no significant differences from BN in atrophy or hypometabolism. SNAP showed increased network concordance compared to BN in the posterior multimodal and language networks. AD continuum showed hypometabolism in all but somatomotor networks and significantly increased atrophy in all but somatomotor and cingulo‐opercular networks. AD continuum showed increased concordance among secondary visual, somatomotor, cingulo‐opercular, dorsal attention, language, auditory, frontoparietal, default mode, posterior, and ventral multimodal networks
T‐scores of false discovery rate–corrected significant networks in suspected non‐Alzheimer's disease pathologic change (SNAP; N = 149) and Alzheimer's disease (AD) continuum (N = 559) groups compared to biomarker normal (BN; N = 179) in W‐score transformed cortical thickness (top panel), fluorodeoxyglucose positron emission tomography (FDG‐PET) hypometabolism (middle panel), and network concordance (bottom panel) after controlling for sex, education, apolipoprotein E ε4, and Clinical Dementia Rating‐Sum of Boxes. SNAP showed no significant differences from BN in atrophy or hypometabolism. SNAP showed increased network concordance compared to BN in the posterior multimodal and language networks. AD continuum showed hypometabolism in all but somatomotor networks and significantly increased atrophy in all but somatomotor and cingulo‐opercular networks. AD continuum showed increased concordance among secondary visual, somatomotor, cingulo‐opercular, dorsal attention, language, auditory, frontoparietal, default mode, posterior, and ventral multimodal networks
Network‐wise concordance stratified by cognitive screening impairment
Figure 5 displays comparisons of network‐wise concordance in CU and CI AD continuum and SNAP versus BN (BN‐unimpaired, n = 158). The CI SNAP (SNAP‐CI, n = 28) showed significantly greater concordance than BN‐unimpaired in the dorsal attention, language, frontoparietal, default mode, and ventral multimodal networks. CU SNAP (SNAP‐CU, n = 121) showed increased concordance compared to BN‐unimpaired in the posterior multimodal network only. CI AD continuum (ADC‐CI, n = 304) revealed significantly greater concordance than BN‐unimpaired in all but the primary visual network. CU AD continuum (ADC‐CU, n = 255) showed significantly greater concordance in the secondary visual, dorsal attention, language, frontoparietal, and default mode networks than BN‐unimpaired.
FIGURE 5
Left panel, T‐scores of false discovery rate (FDR)–corrected significant networks of suspected non‐Alzheimer's disease pathologic change cognitively unimpaired (SNAP‐CU; N = 121) and cognitively impaired (SNAP‐CI, N = 28) SNAP subjects compared to cognitively unimpaired biomarker normal (BN; N = 158) subjects. Right panel, T‐scores of FDR‐corrected significant networks between cognitively unimpaired (ADC‐CU, N = 255) and cognitively impaired (ADC‐CI, N = 304) AD continuum subjects compared to BN subjects
Left panel, T‐scores of false discovery rate (FDR)–corrected significant networks of suspected non‐Alzheimer's disease pathologic change cognitively unimpaired (SNAP‐CU; N = 121) and cognitively impaired (SNAP‐CI, N = 28) SNAP subjects compared to cognitively unimpaired biomarker normal (BN; N = 158) subjects. Right panel, T‐scores of FDR‐corrected significant networks between cognitively unimpaired (ADC‐CU, N = 255) and cognitively impaired (ADC‐CI, N = 304) AD continuum subjects compared to BN subjects
Relationship of network concordance to cognitive change
Among SNAP, increased concordance in the language network at baseline was associated with greater rate of decline in ADNI‐Mem (Figure 6, top left). In AD continuum, greater baseline concordance in the primary visual, somatomotor, dorsal attention, language, frontoparietal, auditory, default mode, and orbito‐affective networks were associated with greater rates of decline in ADNI‐Mem (Figure 6, top right), and greater concordance in the secondary visual, dorsal attention, frontoparietal, and auditory networks were associated with greater rates of decline in ADNI‐EF (Figure 6, bottom right). No relationships were found among BN. Regarding effects of covariates on cognitive change, APOE ε4 positivity negatively impacted rate of ADNI‐Mem decline among the AD continuum group only.
FIGURE 6
T‐scores of network‐wise multivariate regression model assessing for the effect on individual Alzheimer's Disease Neuroimaging Initiative Memory Composite (ADNI‐Mem) and Alzheimer's Disease Neuroimaging Initiative Executive Function Composite (ANDI‐EF) rate of decline in suspected non‐Alzheimer's disease pathologic change (SNAP; N = 139) and Alzheimer's disease (AD) continuum (N = 510), corrected for age, sex, education, apolipoprotein E genotype, and mean W‐score of atrophy and hypometabolism. Top panel, ADNI‐Mem: Significant networks (colored) include language network in SNAP and primary visual, somatomotor, dorsal attention, language, frontoparietal, auditory, default mode, and orbito‐affective networks in AD continuum. There were no significant relationships to ADNI‐Mem rate of change for biomarker normal (BN; N = 167). Bottom panel, ADNI‐EF: Significant networks (colored) for AD continuum include secondary visual, dorsal attention, frontoparietal, and auditory networks. There were no significant relationships to ADNI‐EF rate of change for SNAP or BN
T‐scores of network‐wise multivariate regression model assessing for the effect on individual Alzheimer's Disease Neuroimaging Initiative Memory Composite (ADNI‐Mem) and Alzheimer's Disease Neuroimaging Initiative Executive Function Composite (ANDI‐EF) rate of decline in suspected non‐Alzheimer's disease pathologic change (SNAP; N = 139) and Alzheimer's disease (AD) continuum (N = 510), corrected for age, sex, education, apolipoprotein E genotype, and mean W‐score of atrophy and hypometabolism. Top panel, ADNI‐Mem: Significant networks (colored) include language network in SNAP and primary visual, somatomotor, dorsal attention, language, frontoparietal, auditory, default mode, and orbito‐affective networks in AD continuum. There were no significant relationships to ADNI‐Mem rate of change for biomarker normal (BN; N = 167). Bottom panel, ADNI‐EF: Significant networks (colored) for AD continuum include secondary visual, dorsal attention, frontoparietal, and auditory networks. There were no significant relationships to ADNI‐EF rate of change for SNAP or BN
DISCUSSION
We present the first study to investigate network‐wise concordance of cortical atrophy and glucose hypometabolism, derived from structural MRI and 18FDG‐PET, respectively, among A/T/N biomarker groups. Results revealed that compared to BN, concordance was significantly increased in AD continuum across all except the primary visual and orbito‐affective networks, and SNAP showed greater concordance in the language and posterior multimodal networks. These differences remained statistically significant after accounting for clinical disease severity.Atrophy and 18FDG‐PET hypometabolism may reflect distinct yet complementary neurodegenerative processes.
Studies show that they each uniquely contribute to cognitive decline but also overlap in critical “hub” regions of functional networks.
In these regions, amyloid and tau may promote their synergistic deleterious effects
and “hub”‐based connectivity models have been found to be predictive of longitudinal atrophy in AD
and frontotemporal lobar degeneration (FTLD) syndromes.
These hubs have been proposed within the default mode and frontoparietal cognitive control networks for AD,
which in the present study showed strong concordance for AD continuum. We also found a high degree of atrophy–hypometabolism concordance in SNAP in the posterior multimodal network. The dorsomedial parietal and posterior cingulate regions of this network connect directly with the medial temporal areas that are vulnerable to tau.
This suggests that atrophy–hypometabolism synchrony may be a marker of particular vulnerability to tau pathology among SNAP.Our unimodal analyses showed the expected widespread atrophy and hypometabolism in AD continuum, but little or no increased atrophy or hypometabolism in SNAP. This is consistent with prior research when SNAP was defined by abnormality in CSF p‐tau and t‐tau.
We also showed that SNAP exhibited mild declines on MMSE and memory compared to BN and increased atrophy–hypometabolism concordance in 2 out of 12 networks. Together, these results suggest that SNAP as defined by CSF may represent an early stage of the disease, in which evidence of pathological effects are measurable only in the CSF but not yet robustly in unimodal neuroimaging. Our results support the hypothesis that CSF‐positivity of tau and neurodegeneration markers is likely an early marker along the pathological process leading to SNAP, and concordance markers are superior to unimodal imaging for differentiating from BN at this early stage.Our results showed robust increases in network concordance for AD continuum and only in circumscribed networks for SNAP. The etiology of this difference is likely multi‐determined. First, AD continuum represent a group with greater disease burden than SNAP, as evidenced by their cognitive and clinical severity scores and unimodal neuroimaging findings in the present study. Second, SNAP is hypothesized to be the result of multiple and/or heterogeneous neuropathological processes that may target diffuse brain regions.
,
These diffuse and heterogenous effects are contrasted with a more harmonious neuropathological process driven by Aβ in AD continuum, leading to higher concordance between atrophy and hypometabolism. Thus, our findings support the likelihood that (CSF‐defined) SNAP is etiologically heterogenous. This view is supported by research demonstrating that many non‐AD neurodegenerative pathologies are common in the elderly, with α‐synucleinopathies, non‐AD tauopathies, TDP‐43 proteinopathy, and vascular lesions present in up to 50% of samples.
Given that SNAP in the present study showed elevated CSF Aβ (indicating less Aβ pathology) compared to both AD continuum and BN (P<.01; Table 1), it is unlikely that SNAP represent individuals on the threshold of amyloid positivity, as has been previously suggested.
Given the heterogeneity of the underlying clinicopathological profile of SNAP, it is possible the current sample reflects a limited degree of true “Non‐AD [neurodegenerative] pathology.” However, sufficient noise from diffuse sources of neurodegeneration may also have reduced concordance of atrophy and hypometabolism across several networks.We further examined the heterogeneity in the A/T/N groups by comparing cognitively “unimpaired” (MMSE> = 26) and “impaired” (MMSE<26) participants. Compared to BN unimpaired, unimpaired AD continuum showed greater concordance scores in the secondary visual, dorsal attention, language, frontoparietal, and default mode networks, while 11/12 networks in impaired AD continuum showed higher concordance. In SNAP, the unimpaired showed increased concordance only in the posterior multimodal network, while interestingly the impaired SNAP showed increased concordance across the dorsal attention, language, frontoparietal, default mode, and ventral multimodal networks, in a pattern similar to AD continuum. The association of concordance with cognitive impairment suggests that a synchronous loss of both gray matter structure and metabolism may signal the loss of neuronal capacity that more effectively depletes cognitive reserve and performance than either atrophy or hypometabolism alone.Finally, we examined relationships of individual network concordance measures to 1‐year rates of change in cognitive composites ADNI‐Mem and ADNI‐EF. For AD continuum, memory decline was associated with increased concordance in the dorsal attention, language, frontoparietal, and default mode networks at baseline, and declines in executive functioning were associated with increased concordance in the secondary visual, somatomotor, language, frontoparietal, and default mode networks. These results are consistent with unimodal studies of atrophy and hypometabolism.
,
We also found that the language network showed an association to memory decline in SNAP after accounting for the degree of unimodal atrophy and hypometabolism. Many FTLD syndromes are known to affect the language regions.
Further, atrophy of the ventral, anterior, and medial temporal cortices, which are part of the language network, is seen in familial FTLD.
Future research should examine whether the increased concordance within the language network represents a potential biomarker of neuropathologic change among SNAP who progress to an FTLD syndrome.Strengths of our study include the examination of concordance at the level of functional brain networks, motivated by evidence that neurodegenerative diseases target and spread along large‐scale brain networks.
However, a limitation is that regions of peak concordance may not respect network boundaries.
Alternative, data‐driven measures of concordance may provide important information, including canonical correlation or parallel independent components analysis.Another strength of our study is the use of biomarker‐defined groupings, according to 2018 National Institute on Aging–Alzheimer's Association framework guidelines.
However, limitations do exist in this approach. There are multiple clinical diagnostic entities contained within each group, and whether SNAP represents a distinct biological entity is a matter of debate.
Also, definitions of SNAP differ across studies, including using CSF cut‐offs,
neuroimaging only,
or CSF biomarkers combined with neuroimaging.
These approaches could result in a high degree of variability in clinical or cognitive severity within each A/T/N group, in particular the AD continuum, as up to approximately one‐third of cognitively normal older adults carry AD neuropathologies.
In addition to reporting cognitively impaired versus unimpaired, future studies could also examine those who are only amyloid positive (e.g., A+T–N–) as a separate group.In sum, our findings suggest that network‐level measures of concordance could differentiate SNAP and AD continuum from BN, better than unimodal measures of cortical atrophy and 18FDG‐PET hypometabolism alone. Our findings on the Aβ‐negative SNAP group highlight the importance of abnormal markers of p‐tau or neurodegeneration in the prediction of future cognitive change and suggest that a coordinated relationship between neurodegeneration and cognitive decline can occur in individuals without Aβ. Our findings further support the notion that multimodal neuroimaging analyses are essential to studies of structure–function relationships that contribute to clinical outcomes and diagnostic uncertainty along the biomarker spectrum of AD.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.Supplementary informationClick here for additional data file.
Authors: Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski Journal: Lancet Neurol Date: 2013-02 Impact factor: 44.182
Authors: D A Bennett; J A Schneider; Z Arvanitakis; J F Kelly; N T Aggarwal; R C Shah; R S Wilson Journal: Neurology Date: 2006-06-27 Impact factor: 9.910
Authors: Jane Stocks; Karteek Popuri; Ashley Heywood; Duygu Tosun; Kate Alpert; Mirza Faisal Beg; Howard Rosen; Lei Wang Journal: Alzheimers Dement (Amst) Date: 2022-04-26
Authors: Suzee E Lee; Maria C Tartaglia; Görsev Yener; Sermin Genç; William W Seeley; Pascual Sanchez-Juan; Fermin Moreno; Mario F Mendez; Eric Klein; Rosa Rademakers; Adolfo López de Munain; Onofre Combarros; Joel H Kramer; Robert O Kenet; Adam L Boxer; Michael D Geschwind; Maria-Luisa Gorno-Tempini; Anna M Karydas; Gil D Rabinovici; Giovanni Coppola; Daniel H Geschwind; Bruce L Miller Journal: Alzheimer Dis Assoc Disord Date: 2013 Oct-Dec Impact factor: 2.703
Authors: Renaud La Joie; Alexandre Bejanin; Anne M Fagan; Nagehan Ayakta; Suzanne L Baker; Viktoriya Bourakova; Adam L Boxer; Jungho Cha; Anna Karydas; Gina Jerome; Anne Maass; Ashley Mensing; Zachary A Miller; James P O'Neil; Julie Pham; Howard J Rosen; Richard Tsai; Adrienne V Visani; Bruce L Miller; William J Jagust; Gil D Rabinovici Journal: Neurology Date: 2017-12-27 Impact factor: 9.910
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Jane Stocks; Karteek Popuri; Ashley Heywood; Duygu Tosun; Kate Alpert; Mirza Faisal Beg; Howard Rosen; Lei Wang Journal: Alzheimers Dement (Amst) Date: 2022-04-26